Introduction
In the course of a systematic screen ing program all potentially psycho active substances which had been clini cally studied in our hospitals were test ed in regard to their effect on dextraninduced increased capillary permeability in rats (8, 12 ). This procedure was based on the observation that specific amounts of dextran "induce maximal edema formation" in the shortest time, whereas a certain critical dose of dextran does not produce any edema at all (6, 7). To explain this phenomenon it was sug gested that the dextran macromolecule has two reactive sites: one edema pro voking (EP) and another edema inhibit ing (EI). Further investigations revealed that pharmacological agents which react in vivo with EP and inhibit edema form ation are clinically chlorpromazine-type antipsychotic (neuroleptic) drugs. The first clinically explored thioxanthene de rivative, chlorprothixene*, exerted a stronger edema inhibiting effect than any of the antipsychotic phenothiazine pre parations. Since all other thioxanthenes tested by us, that is clopenthixol** and thiothixene***, had a qualitatively similar action, we undertook systematic investi gations with this potentially antipsycho tic group of substances (11).
The thioxanthenes are the result of the unprecedented success of the phenothiazines in the treatment of schizo phrenic patients which stimulated the search for new synthetic chemicals with antipsychotic properties. In the course of systematic exploratory work, Petersen et al. (16) succeeded in synthesizing chlorprothixene, the chlorpromazine analogue of the thioxanthene series. This substance has potent psychotropic action, while its toxic and adverse effects, for example blood dyscrasias, liver damage, photosensitivity, extrapyramidal signs and depression appear to be markedly less than those of the phenothiazines (1) .
In the thioxanthenes the nitrogen (N) atom in position ten of the phenothiazine nucleus is replaced by a carbon (C) atom ( Figure I ). Since the C in the thioxanthenes has no free electrons, in contradistinction to the N in the pheno thiazines, the newly synthesized struc ture was found to be less aromatic than the parent substance (17).
Chlorprothixene, the first thioxan thene derivative, was introduced in 1959; clopenthixol, the second, in 1961; and thiothixene, the third, six years later (1) . In subsequent clinical studies it was re cognized that chlorprothixene was in ferior to chlorpromazine**-and also to haloperidol***-in the treatment of acute
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The Structural Formulae of Thiothixene, a Thioxanthene and of Thioproperazine, a Phenothiazine schizophrenics, and inferior to trifluoper azine**** in the therapy of chronic schizophrenic patients (9, 12). It was also recognized that clopenthixol exerts a particularly beneficial effect on affec tive psychopathological manifestations, in contradistinction to perphenazine^ which primarily improves mental integration (2) . On the other hand the place of the third compound, thiothixene, which is gradually being more frequently em ployed in the treatment of schizophrenic patients, has not yet been fully estab lished (19).
Thiothixene, a new antipsychotic drug -review of literature
Thiothixene is the thioxanthene ana logue of thioproperazine, an extensively used phenothiazine -neuroleptic drug ( Figure I ). Animal pharmacological studies in rats have shown that the new substance interferes with conditioned avoidance responses in doses which do not affect the unconditional escape re-****Stelazine §Trilafon To date there are more than eighty published reports on the clinical effects of thiothixene confirming its therapeutic effects in acute and chronic schizo phrenics (11, 15). However, a compre hensive report, based on a series of stud ies under similar conditions on a large number of patients, is still lacking. To fill this gap a series of systematic studies was designed to establish the therapeutic profile of thiothixene in the treatment of schizophrenic patients.
Systematic studies with thiothixene
Our systematic investigations with thiothixene consisted of five clinical studies. Findings of the first four of these are reported in this paper.
Pilot Study
This study was carried out on twenty therapy-resistant chronic schizophrenic patients (13 males and 7 females), select ed from the inpatient population of the Douglas Hospital. The age of the patients ranged from 22 to 69 years (with a mean of 46.7 and a median of 46 years) and they had been hospitalized for four to forty years (with a mean of 20 and a median of 16 years).
After a minimum drug-free period of one week, all the patients included in this study were placed on thiothixene for an eight-week period. The initial daily dose of the investigational substance was 10 mg., administered in two divided doses, which was gradually increased until a maximum daily dose of 60 mg. was reached, or until a marked clinical im provement was noted. In most cases this was achieved by about the fifth week while receiving (orally) daily 30 to 40 Out of twenty only two patients had to be taken off the clinical trial. One of these patients developed severe hypo tension. The other had a cerebral seizure within 24 hours after receiving the first dose of the investigational drug. This latter patient had a history of epilepsy, but had had no cerebral seizure for at least five years prior to thiothixene ad ministration.
It was our clinical impression that most patients became more animated by the third and fourth weeks of treatment. Around the same time they had better emotional contact and were more aware of their surroundings than prior to com mencement of therapy with the investi gational substance (21). Statistically significant ('t' test) improvement occur red (Table I ) only in total symptomato logy (P < 0.05) after four weeks of treatment, while by the time of termina tion of the clinical trial statistically significant improvement was also noted in motor retardation (P < 0.05) and suspiciousness (P < 0.05). There was a trend for improvement in hallucinatory behaviour (P < 0.07).
Besides hypotension and cerebral sei zure one patient complained of dizziness in the initial stages of drug administra tion and another became depressed and expressed suicidal ideation during the sixth week. Seven other patients develop ed extrapyramidal signs, that is tremors (three patients), oculogyric crises (three patients) and akathisia (one patient).
Uncontrolled study
This was carried out at Hopital des Laurentides on twenty inpatients (16 males and 4 females) ranging in age from 19 to 53 years (with a mean of 34 and a median of 36 years). Ten of the patients included in this study were chronically hospitalized schizophrenics and the other ten were newly admitted cases. The length of present hospitalization of the chronic group ranged from three to sixty months (with a mean of 30 and a median of 24 months).
After a minimum drug-free period of two weeks the chronic patients were placed on thiothixene for a twelve-week period. The acute patients were includ ed in the study immediately following their admission to the hospital. The ini tial daily dose of the investigational sub stance was 10 mg., administered in two divided doses, which was gradually in creased until a maximum daily dose of 80 mg. was reached, or an optimum degree of therapeutic benefit was seen. In most of the acute cases this was achieved by about the fifth week while receiving (orally) 30 to 40 mg. a day of the drug. In some patients, however, the dosage had to be further increased, up to 50 mg. per day in two cases and to the maximal dosage of 80 mg. in one case, to attain optimal therapeutic results. The median administered dose for the chronic group was 75 mg. daily. Assessment of clinical changes follow ed the same basic design as of the pilot study.
Out of twenty only three patients had to be taken off the twelve weeks clinical trial. One 34-year-old, acute paranoid, schizophrenic male patient was taken off the investigation after four weeks of treatment because of progressive wors ening of his condition; another 32-year old, acute paranoid schizophrenic male was discontinued because of administra tive reasons (transfer to another hospital) and a third 35-year old, acute paranoid schizophrenic female died. This latter patient, with a history of alcoholism and occasional cerebral seizures, was clinical ly improving on thiothixene medication.
Her death was due to an epileptic fit which she had in the tenth week of treat ment while receiving 50 mg. daily of the investigational drug.
It was our clinical impression that thiothixene administration resulted in better therapeutic effects in the newly admitted than in the chronically hospi talized population. While statistically significant ('t' test) changes did not occur in the chronic group at any time during the study, the combined (acute and chronic) group showed statistically significant improvement after eight weeks of treatment (Table II) on the symptoms of suspiciousness (P < 0.05) and at the time of termination of the study on total symptomatology (P < 0.05). There was also a trend for im provement in unusual thought content (P < 0.07). Analysis of findings in the acute group yielded the most statistically significant improvement in total symp tomatology (P < 0.05), suspiciousness (P < 0.02), and hallucinatory behaviour (P < 0.05) after four weeks of treatment. Furthermore, after eight weeks of treat ment the improvement in grandiosity (P < 0.01), unusual thought content (P < 0.01) and excitement (P < 0.05) had also reached statistical significance.
Besides cerebral seizures the major side effects were extrapyramidal in nature in both groups. A total of eight casesfive acute and three chronic -presented extrapyramidal signs; three patients (one acute and two chronic) showed drow siness at the initial period of treatment and two (one acute and one chronic) complained of dizziness in the course of the drug study.
Controlled studies
First study
This was carried out on thirty inpa tients (22 males and eight females) at Hopital des Laurentides, ranging in age from 17 to 46 years (with a mean of 29.6 and a median of 28 years). Fifteen of the patients included in this study were chronically hospitalized schizophrenic patients and the other fifteen were new ly admitted cases. The length of present hospitalization of the chronic group ranged from one to 71 months (with a mean of 21 and a median of eight months).
Three treatment groups were formed. There were no significant differences in sex and age in the three groups. The thiothixene treated group consisted of eight males and two females while the chlorpromazine and the placebo treated groups consisted of seven males and three females each. The mean age of the thiothixene treated group was 27.5 years, of the placebo treated group 29.7 and of the chlorpromazine treated group 31.7 years.
After a minimum drug-free period of two weeks the chronic patients were placed on one of the three treatment regimes on the basis of a randomized double-blind design. The acute patients were included in the study immediately following their admission to the hospital. All medication was supplied in capsules identical in appearance. Each capsule contained either 5 mg. of the investiga tional substance, (i.e. thiothixene) or 100 mg. of the standard drug, i.e. chlorpro mazine, or an inactive placebo. Drugs were administered on the basis of a fixed dosage schedule starting with two cap sules a day, given in two divided doses and reaching a maximum of eight cap sules daily during the seventh week of treatment.
Assessment of clinical changes fol lowed the same basic design as in the former studies.
Out of the thirty patients, twenty had to be taken off before the termination of the twelve-week clinical trial. They were almost equally distributed among the three groups. It was noted, however, that of the thiothixene patients, only three were taken off the study because of worsening of their clinical condition and two because of unsatisfactory thera peutic response, while in another two, thiothixene administration was discon tinued because of the rapid improve ment which resulted in their discharge from hospital. The same applies to the chlorpromazine treated patients. Of the six patients who did not complete the clinical trial from this group, only in three was this the result of worsening of their clinical condition, while in the remaining three the rapid clinical im provement led to discharge from hospital and consequently to withdrawal of the medication. On the other hand none of the patients from the placebo group were taken off the drug study because of clinical improvement, while four had to be discontinued because of worsen ing of their clinical state, two because of unsatisfactory therapeutic progress and one because of administrative rea sons.
The clinical course described was re flected in the statistically significant ('t' test) clinical changes. The placebo group as a whole did not show any therapeutic changes. If anything, there was a significant increase in emotional withdrawal (P < 0.05) in this group after four weeks of treatment. Of the two active treatment groups (including acute and chronic patients) significant im provement occurred in six of the psychopathological areas under the influence of thiothixene and in two under the in fluence of chlorpromazine (Table III) . Emotional withdrawal (P < 0.05), con ceptual disorganization (P < 0.05), gran diosity (P < 0.05), hallucinatory be haviour (P < 0.02), blunted affect (P < 0.02) and disorientation (P < 0.05) sig nificantly improved after four weeks of treatment in the thiothixene group, while in the chlorpromazine treated patients only unusual thought content (P < 0.05) showed significant improvement within the same period of time, and the im provement in disorientation (P < 0.05) reached the acceptable level of statistical significance only by the time of the eight weeks' assessment. A significant worsen ing in motor retardation (P < 0.05) was found in the chlorpromazine treated patients (19).
In none of the three treatment regimes did any significant change occur in the chronic groups of patients. On the other hand thiothixene treated acute cases im proved significantly in conceptual dis organization (P < 0.05), suspiciousness (P < 0.05), hallucinatory behaviour (P < 0.02), unusual thought content (P < 0.02), disorientation (P < 0.02), as well as in their total symptomatology (P < 0.02) after four weeks; and chlorpro mazine treated acute cases improved significantly in anxiety (P < 0.05) after four and in unusual thought content (P < 0.05) after eight weeks of treatment (Table IV) .
Prevailing side effects were extra pyramidal manifestations (thiothixene: five cases and chlorpromazine: two cases), coupled with drowsiness in three on chlorpromazine and with insomnia in one case on thiothixene. In one chronic 46-year old female patient a cerebral sei zure occurred in the third week of chlor promazine treatment.
Second Study
This was carried out at Hopital des Laurentides on thirty inpatients (18 males and 12 females), ranging in age from 20 to 53 years (with a mean and median of 35 years). Fifteen of the patients includ ed in this study were chronically hospi talized schizophrenic patients and the other fifteen were newly admitted cases. The length of present hospitalization of the chronic group ranged from two to 75 months (with a mean of 31 and a median of 23 months).
It was noted that sex distribution was equal in the thioproperazine group; it was in favour of females in the thio thixene (6:4) and strongly in favour of males (9:1) in the chlorprothixene treat ed patients. Mean length of hospitalization was also the longest in this group (52 months), more than four times as long as in the thiothixene (12 months) treated patients and almost twice as long as in the thioproperazine (27 months) group. On the other hand the mean age of the chlorprothixene group was the lowest (34 years) and of the thiothixene treated group the highest (40 years); the thio properazine treated group being in be tween (36 years). After a minimum drug-free period of two weeks the chronic patients and acute patients, immediately following their ad mission, were placed on one of three treatment regimes on the basis of a ran domized double-blind design. All medi cation was supplied in capsules identical in appearance, size, shape, colour, odour and taste. Each capsule contained either 5 mg. of thiothixene, or 75 mg. of chlor prothixene, or 1.5 mg. of thiopropera zine.
ITEMS OF THE BPRS ON WHICH SIGNIFICANT ('T' TEST) IMPROVEMENT OCCURRED IN THE ACUTE SUBPOPULATIONS AFTER THE 4TH, THE 8TH AND THE 12TH WEEKS OF TREATMENT IN THE THIOTHIXENE (T) AND CHLORPROMAZINE (C) TREATED GROUPS
Items
A fixed dosage regime was followed in the first three weeks of the clinical trial and a flexible dosage regime for the remaining nine weeks. The fixed dosage regime consisted of the adminis tration of two capsules in divided doses daily during the first week, four cap sules daily during the second and six capsules daily during the third week. Thereafter the number of capsules ad ministered daily was adjusted. Adjust ment was dependent upon the individual variation in therapeutic response or ad verse effects to the drug. The total num ber of capsules, however, was kept between a minimum of two and a maxi mum of eight capsules daily (19).
Assessment of clinical changes follow ed the same basic design as in the former studies.
Out of thirty patients, nineteen had to be taken off before the termination of the twelve-week clinical trial. It was noted, however, that in all five of the thiothixene treated patients drug admin istration was discontinued because of the rapid clinical improvement which result ed in their discharge from hospital. On the other hand five patients in the thio properazine treated group and three in the chlorprothixene treated group were taken off medication because of worsen ing of their clinical condition (and only three and two respectively because of rapid improvement and discharge). An other chlorprothixene treated patient had to be taken off the study for admin istrative reasons.
The least statistically significant ('t' test) clinical changes occurred in the chlorprothixene treated group (Table  V) , but even in this group there was a significant improvement after four weeks of treatment in tension (P < 0.05) and depressive mood (P < 0.05). In both thiothixene and thioproperazine treated groups there was a significant improve ment after four weeks in suspiciousness (P < 0.02), hallucinatory behaviour (P < 0.02) and unusual thought content (P < 0.01). At the same time, differen tially the thiothixene group improved in mannerisms, posturing (P < 0.02) and disorientation (P < 0.05); and the thio properazine group improved in grandios ity (P < 0.05), depressive mood (P < 0.02), hostility (P < 0.05) and excite ment (P < 0.05). In neither of the three treatment re gimes did any significant change occur in the chronic group of patients. There was, however, a trend towards improve ment in suspiciousness (P < 0.06) and blunted affect (P < 0.06) in the thiopro perazine group at the time of the twelve weeks' assessment. Significant improve ment was seen in ten items of the BPRS in the acute thiothixene, in eight items in the acute thioproperazine and in four items in the acute chlorprothixene treat ed groups (Table VI) . Significantly im proved symptoms with thiothixene were anxiety (P < 0.02), emotional with drawal (P < 0.05), conceptual disorgan ization (P < 0.05), mannerisms and pos turing (P < 0.02), depressive mood (P < 0.05), suspiciousness (P < 0.01), hall ucinatory behaviour (P < 0.01), unus ual thought content (P < 0.02), dis orientation (P < 0.05) and total symp tomatology (P<0.02); with thiopro perazine, grandiosity (P < 0.05), de pressive mood (P < 0.02), hostility (P < 0.05), suspiciousness (P < 0.01), hall ucinatory behaviour (P < 0.01), unus ual thought content (P < 0.01), excite ment (P < 0.01) and total symptoma tology (P<0.02); and with chlorpro thixene, conceptual disorganization (P < 0.05), mannerisms and posturing (P < 0.05), grandiosity (P < 0.02), and hallucinatory behaviour (P < 0.01).
TABLE V BPRS ITEMS ON WHICH SIGNIFICANT ('T' TEST) IMPROVEMENT OCCURRED IN THE THIOTHIXENE (T), THIOPROPERAZINE (TP) AND CHLORPROTHIXENE (CH) TREATED GROUPS AFTER THE 4TH, THE 8TH AND THE
Prevailing side effects were extra pyramidal manifestations (thiothixene: five cases; thioproperazine: three cases; chlorprothixene: one case). Cerebral seizure occurred in one 41-year old chronic schizophrenic male patient dur ing the tenth week of thioproperazine administration and in one 2 2-year old acute schizophrenic male patient during the second week of chlorprothixene ad ministration. 
Discussion
In the course of systematic studies, sixty hospitalized schizophrenic patients were given thiothixene in the dosage range of 10 to 80 mg. a day (average dosage 30 to 40 mg.) over an eight (20 patients) to twelve-week period. Of the total population, 35 were males and 25 were females with an age range of 19 to 69 years (mean: 36.7 and median: 38). Twenty of the patients were newly ad mitted and forty chronically hospitaliz ed. The length of hospitalization of the latter group ranged from 18 months to 40 years with a mean of 6.2 and a median of 4.8 years.
All patients were assessed on the BPRS prior to the conmmencement of drug ad ministration and thereafter at two week ly intervals. Simultaneously with the psychiatric assessment, side effects were looked for, laboratory tests were done and a routine physical examination was performed.
In the total population including acute and chronic patients, statistically signifi cant ('t' test) improvement was seen in total symptomatology (P < 0.05), as well as in symtoms primarily reflecting the psychological parameter of mental integration after four weeks of treat ment. It was noted, however, that there was also a significant improvement in blunted affect (P < 0.05) at the time of the one month assessment. Significantly improved symptoms were conceptual disorganization (P < 0.05), mannerisms and posturing (P < 0.05), suspiciousness (P < 0.05), hallucinatory behaviour (P < 0.05), unusual thought content (P < 0.05) and disorientation (P < 0.05). While in the chronic population im provement in none of the symptom areas reached the level of statistical signifi cance ('t' test), there was a definite trend towards improvement in this group in suspiciousness (P < 0.06) and hallu cinatory behaviour (P < 0.06). On the other hand, in the acute population, significant improvement occurred after four weeks of treatment in total symp tomatology (P < 0.02) and in the fol lowing symptoms: conceptual disorgan ization (P < 0.05), mannerisms and pos turing (P < 0.05), grandiosity (P < 0.05), suspiciousness (P < 0.02), hallu- cinatory behaviour (P < 0.02), unusual thought content (P < 0.05) and dis orientation (P < 0.05) (Table VII) . Of the total of 60 patients seventeen were taken off drug administration be fore termination of the clinical trial: eight because of the worsening in over all psychopathology, two because of in sufficient therapeutic response within a four-week period and seven because of rapid marked therapeutic improvement which resulted in discharge from hospi tal.
Adverse effects in the course of clini cal trial were prevailingly extrapyramidal manifestations, which occurred in more than forty per cent of the total popula tion. They were, however, easily con trolled by either reduction of the dosage or by the administration of an antiparkinson drug. The incidence of cerebral seizure, the second important adverse ef fect recognized, is low (3%). This was seen only in patients with a history of convulsions.
Conclusions and Summary
On the basis of a pilot study carried out in twenty chronically hospitalized psychiatric patients, thiothixene was sug gested to have psychotropic properties.
The psychotropic properties of thio thixene were supported by the results of an uncontrolled clinical pharmacological study carried out on a total of twenty, including ten acute and ten chronic, schizophrenic patients. In the same study antipsychotic properties were revealed.
The antipsychotic properties of thio thixene were supported in two controlled clinical investigations in which the thera peutic effects of thiothixene were found to be significantly superior to an inactive placebo and comparable to at least three other antipsychotic drugs.
The range of therapeutic activity, an almost exclusive effect on symptoms re lated to the psychological parameter of mental integration, associated with a beneficial effect on blunted affect, dif ferentiates thiothixene from chlorproma zine, thioproperazine and chlorpro thixene.
For most of the patients the thera peutic dosage of thiothixene ranges be tween 30 to 40 mg. a day.
In acute schizophrenic patients sig nificant therapeutic changes with thio thixene were seen within four weeks.
Twelve weeks is insufficient to pro duce statistically significant therapeutic changes with thiothixene in chronic schizophrenic patients.
Side effects to thiothixene are mini mal. They are prevailingly extrapyra midal manifestations which can be easily controlled by reduction of dosage or antiparkinsonian medications.
Thiothixene reduces the convulsive threshold and thus predisposes to cere bral seizures. However, the incidence of this adverse effect, is low. tant sur vingt schizophrenes, dont dix aigus et dix chroniques. Cette etude indiquait aussi que le produit jouissait de proprietes antipsychotiques.
Deux etudes controlees devaient confirmer les proprietes antipsychotiques de la thiothixene et etablir en outre que son efficacite therapeutique etait superieure a celle d'un placebo et comparable a trois autres antipsychotiques.
En ce qui concerne le champ de l'activite therapeutique, ce qui semble differencier la thiothixene de la chlorproma zine, de la thioproperazine et de la chlorprothixene serait son action presqu' exclusive sur l'emoussement des affects et sur les symptomes traduisant une pathologie de l'integration mentale et des associations.
Pour la plupart des patients la dose therapeutique de thiothixene variait entre 30 et 40 mg. par jour.
Chez les schizophrenes aigus, les ef fects therapeutiques se faisaient sentir en moins de quatre semaines.
Par contre, avec les schizophrenes chroniques, meme une periode de douze semaines ne permet de mettre en evidence des resultats therapeutiques significatifs.
Les effets secondaires de la thiothixene soit minimes. lis consistent essentiellement en manifestations extrapyramidales, facilement controlees par reduction de la dose ou administration d'antiparkinsoniens.
La thiothixene abaisse le seuil convulsif et predispose ainsi aux crises cerebrales. II s'agit la, cependant d'une reaction exceptionelle.
